<table border="0" id="t38707699" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3:  Clinically Relevant Interactions Affecting Naldemedine
When Co-Administered with Other Drugs</caption>
<colgroup>
<col></col>
<col></col>
</colgroup>
<tbody>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Strong CYP3A
Inducers (e.g., rifampin, carbamazepine, phenytoin, St. Johnâ€™s Wort)</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical Impact</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Significant decrease in plasma
naldemedine concentrations, which may reduce efficacy <content stylecode="italics">[see
Clinical Pharmacology (<linkhtml href="#Secton_12.3">12.3</linkhtml>)]</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Avoid use of SYMPROIC with strong
CYP3A inducers.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Other Opioid
Antagonists</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical Impact</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Potential for additive effect
of opioid receptor antagonism and increased risk of opioid withdrawal.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Avoid use of SYMPROIC with another
opioid antagonist.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Moderate (e.g.,
fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and
Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir,
saquinavir) CYP3A Inhibitors</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical Impact</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Increase in plasma naldemedine
concentrations <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor for potential naldemedine-related
adverse reactions <content stylecode="italics">[see Adverse Reactions (<linkhtml href="#Section_6.1">6.1</linkhtml>)]</content>.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">P-glycoprotein
(P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin,
quinidine, verapamil)</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical Impact</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Increase in plasma naldemedine
concentrations <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor for potential naldemedine-related
adverse reactions <content stylecode="italics">[see Adverse Reactions (<linkhtml href="#Section_6.1">6.1</linkhtml>)]</content>.</td>
</tr>
</tbody>
</table>